Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 0 | 0 | 3,551 | 16,097 | 15,825 |
| Gross Profit | N/A | N/A | 3,551 | 16,097 | 15,825 |
| Operating Expenses | 176,141 | 126,191 | 140,096 | 124,427 | 118,528 |
| Operating Income | -176,141 | -126,191 | -136,545 | -108,330 | -102,703 |
| Interest Expense | 5,094 | 7,244 | 5,367 | 5,262 | 5,158 |
| Other Income | 7,258 | 6,439 | 3,223 | 4,602 | 4,478 |
| Pre-tax Income | -173,977 | -126,996 | -138,689 | -108,990 | -103,383 |
| Income Tax | N/A | N/A | -3,313 | 2,025 | 742 |
| Net Income Continuous | -173,977 | -126,996 | -135,376 | -111,015 | -104,125 |
| Minority Interests | -3,184 | -1,696 | -2,512 | -1,336 | -1,179 |
| Net Income | $-170,793 | $-125,300 | $-132,864 | $-109,679 | $-102,946 |
| EPS Basic Total Ops | -1.38 | -1.02 | -1.24 | -1.03 | -0.96 |
| EPS Basic Continuous Ops | -1.40 | -1.03 | -1.26 | -1.04 | -0.97 |
| EPS Diluted Total Ops | -1.38 | -1.02 | -1.24 | -1.02 | -0.96 |
| EPS Diluted Continuous Ops | -1.40 | -1.03 | -1.26 | -1.03 | -0.97 |
| EPS Diluted Before Non-Recurring Items | -1.38 | -1.02 | -1.24 | -1.03 | -0.96 |
| EBITDA(a) | $-164,369 | $-119,935 | $-133,117 | $-105,458 | $-100,375 |